Overall, these findings show that there are many ways NK cell activity is reduced in cancer, influenced by epigenetic enzymes like SIRTs (SIRT1, SIRT2, SIRT6), surface regulators like CD38, and signaling pathways like TGFβ-SMAD4. Here, SIRT1 is linked to cancer.